{"id":909012,"date":"2025-11-12T12:16:49","date_gmt":"2025-11-12T17:16:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/"},"modified":"2025-11-12T12:16:49","modified_gmt":"2025-11-12T17:16:49","slug":"sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/","title":{"rendered":"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8211; Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC &#8211;\u00a0<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>&#8211; Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 &#8211;<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>&#8211; Investor webcast today at 7:00AM PT \/ 10:00AM ET &#8211;<\/em>\n      <\/p>\n<p>SOUTH SAN FRANCISCO, Calif., Nov.  12, 2025  (GLOBE NEWSWIRE) &#8212; Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), is hosting a virtual R&amp;D Day today highlighting the details of its platform innovation and next-generation ADC pipeline. The presentation will include an overview of Sutro\u2019s near- and long-term priorities, beginning with STRO-004, its potential best-in-class Tissue Factor ADC, which has now entered clinical development. The Company will also provide details on its dual-payload ADC programs, uniquely enabled by its proprietary cell-free platform, and reveal STRO-227, its first dual-payload candidate designed to target PTK7.<\/p>\n<p>\u201cThe programs we are advancing showcase our platform\u2019s unique potential to meaningfully expand the therapeutic window and address some of the most persistent challenges with conventional ADCs,\u201d said Jane Chung, Sutro\u2019s Chief Executive Officer. \u201cWith STRO-004 entering the clinic and our dual-payload programs accelerating, we are positioned to deliver ADCs that combine optimized target engagement, differentiated design, and industry-leading pharmacokinetics to enable deeper and more durable responses to redefine what is possible for cancer care.\u201d<\/p>\n<p>Ms. Chung continued: \u201cThe selection of PTK7 for our initial dual-payload program underscores our strategy to address difficult-to-treat solid tumors where standard approaches have been insufficient. Additionally, through strategic collaborations including our partnership with Astellas, we continue to broaden the impact of our ADC technology and advance novel payload combinations to deliver therapies with the potential to transform the standard of care to patients.\u201d<\/p>\n<p>The event will feature presentations by key members of Sutro\u2019s senior management team and Anthony Tolcher, M.D., FRCPC, FACP, a medical oncologist and founder and head of NEXT Oncology. Sutro management will participate in a Q&amp;A session at the end of the presentation.<\/p>\n<p>\n        <strong>Next-Generation ADC Innovation<\/strong><br \/>\n        <br \/>Sutro\u2019s platform is designed to optimize every component of an ADC\u2014the antibody, linker, and payload\u2014rather than focusing on one or two elements in isolation. This holistic control is enabled by the Company\u2019s cell-free technology, which allows unparalleled flexibility in designing ADCs and the potential to dose higher due to optimized safety and efficacy, even in complex biological settings. In addition, the platform enables sophisticated dual-payload combinations, enabling therapies that could redefine the standard-of-care.<\/p>\n<p>\n        <strong>Program Highlights and Near-Term Pipeline Milestones<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>Single-payload ADC Programs<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Single-payload programs will establish Sutro\u2019s foundation by tackling hard-to-reach, complex targets.<\/p>\n<ul type=\"disc\">\n<li>STRO-004: A potential best-in-class Tissue Factor (TF) targeting ADC, STRO-004, has entered clinical trials following recent IND clearance from the U.S. Food and Drug Administration (FDA). In preclinical TF-expressing models of head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, and pancreatic cancer, STRO-004 showed promising anti-tumor activity. Combined with a highest non-severely toxic dose of 50 mg\/kg in non-human primate studies, STRO-004 is anticipated to meaningfully widen the therapeutic window versus conventional ADCs to address a wide range of tumors of unmet need.\n<\/li>\n<li>STRO-006:\u00a0A potential best-in-class, highly selective integrin \u03b26 (ITGB6) targeting ADC, STRO-006, has demonstrated a superior pharmacokinetic profile compared to the current ITGB6-targeting ADC in Phase 3 development. Additionally, STRO-006 demonstrated encouraging anti-tumor activity and duration of response in preclinical models. STRO-006 is expected to enter clinical development in 2026 for the treatment of multiple solid tumors.\n<\/li>\n<\/ul>\n<p>\n        <strong><br \/>\n          <em>Dual-Payload ADC Program<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Sutro\u2019s dual-payload ADCs are designed to overcome resistance, delay progression, and potentially set a new standard-of-care by unlocking durable efficacy.<\/p>\n<ul type=\"disc\">\n<li>STRO-227: Sutro has selected tyrosine-protein kinase-like 7 (PTK7) as the target for its initial dual-payload candidate. PTK7 is overexpressed in many different cancers, including breast, lung, ovarian and colorectal cancer. The Company is working to accelerate its dual-payload ADC program, with an IND submission now targeted for 2026\/2027.\n<\/li>\n<\/ul>\n<p>\n        <strong><br \/>\n          <em>Summary of Pipeline Milestones <\/em><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>STRO-004: Phase 1 study ongoing; initial data expected mid-2026<\/li>\n<li>STRO-006: IND submission targeted for 2026<\/li>\n<li>STRO-227: IND submission targeted for 2026\/2027\n<\/li>\n<\/ul>\n<p>\n        <strong><br \/>\n          <em>Next-Generation ADC Collaborations<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Research and development programs are progressing under Sutro\u2019s collaboration, with Astellas focused on dual-payload immunostimulatory ADCs (iADCs). The first iADC program is expected to enter the clinic in early 2026.<\/p>\n<p>\n        <strong>Webcast Information:<\/strong><br \/>\n        <br \/>To access the live audio webcast beginning at 7:00AM PT \/ 10:00AM ET, please go to\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2EiwqX07rsooTI-OCmBM0XHl_AaEzN5DJyQYr6uSMtuk8wHHxod6rt1l-4BpcbGlO5-P6V8Ut1z0ZD_4u0GLNO-8wHdD_5xVIscDwE5qkZA37N4Y_lbF5JPwT0HbnntoUtJoj_I4jjqNTU49BgCsR6KiyPomVL8A4s7fiKhToDssBMM9gXGwkzMl52y2QRGZUtSOXs6iA3-2yxe5aZ4v-6W16pGYzcNaxnEcj3P6shffVIjg9Fr5BWX48wRmYpLphjV6t-SKrMKxo9DryVI6WxbfLPpkiFh9A5a_LWyHo8hzoQPs0hPjX3lT-e9pF_TjLF53bVZIfAS2LBYhECviGLWzxLeA56neChAZGI0Rfw3FIj06G0rkk67L_TWEIO30ld3X2opIQmTpQ7dy-pIBWA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.sutrobio.com\/news-events\/ir-calendar<\/a>. An archived replay of the webcast will be available on the Company\u2019s website following the event.<\/p>\n<p>\n        <strong>About Sutro Biopharma \u00a0<\/strong><br \/>\n        <br \/>Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro\u2019s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what\u2019s possible in cancer therapy. The Company\u2019s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.<\/p>\n<p>For more information, follow Sutro on social media @Sutrobio or visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l8tHuI1dZlfV8DPoEckYlnU0OR-Ip8opGhlRLd0M5K9eEaVh2x9An3Z_4xM1fjQTHo7KQc7q4iiH6B1LwWPB_K-6JoAiaBAM3auCG9pJEIE=\" rel=\"nofollow\" target=\"_blank\">www.sutrobio.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities; timing of announcements of IND submissions, trial initiation, clinical results, and other regulatory filings; outcome of discussions with regulatory authorities; potential benefits of the Company\u2019s product candidates and platform; potential business development and partnering transactions; potential market opportunities for the Company\u2019s product candidates and the timing and receipt of anticipated future milestone payments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company\u2019s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company\u2019s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company\u2019s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company\u2019s ability to obtain, maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company\u2019s ability to fund development activities and achieve development goals, the Company\u2019s ability to protect intellectual property, and the Company\u2019s commercial collaborations with third parties and other risks and uncertainties described under the heading \u201cRisk Factors\u201d in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.\u00a0<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Emily White<br \/>Sutro Biopharma<br \/>(650) 823-7681<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GG75zLrj2YUwSp3gTjiZdo1T2N-Ng2s4g4A2cAjslRUGIS0otOO2C9bxLxoOYEPUB6oYg97ioBEM0FcMLTwiEtcYijtCfb3LbwGs1udusb0=\" rel=\"nofollow\" target=\"_blank\">ewhite@sutrobio.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Amy Bonanno<br \/>Lyra Strategic Advisory<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S8QIoGiNeuDP6L2CWastTmHgjcBlBztrHQn9riLclOcZjtaaqkaZ8_6ler6bHrLtwHcYxJinjozg7A493lJ6goLJ57Lt-Gic7rCU9MrxHV1msrHPxoLeP5kz5uXzgrCa\" rel=\"nofollow\" target=\"_blank\">abonanno@lyraadvisory.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTI1ZmRiOWEtMmE0Ni00YzYxLWI4YjQtYjMwYzZjMjM1YjBjLTExMzUzMzUtMjAyNS0xMS0xMi1lbg==\/tiny\/Sutro-Biopharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC &#8211;\u00a0 &#8211; Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 &#8211; &#8211; Investor webcast today at 7:00AM PT \/ 10:00AM ET &#8211; SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), is hosting a virtual R&amp;D Day today highlighting the details of its platform innovation and next-generation ADC pipeline. The presentation will include an overview of Sutro\u2019s near- and long-term priorities, beginning with STRO-004, its potential best-in-class Tissue Factor ADC, which has now entered clinical development. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-909012","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC &#8211;\u00a0 &#8211; Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 &#8211; &#8211; Investor webcast today at 7:00AM PT \/ 10:00AM ET &#8211; SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), is hosting a virtual R&amp;D Day today highlighting the details of its platform innovation and next-generation ADC pipeline. The presentation will include an overview of Sutro\u2019s near- and long-term priorities, beginning with STRO-004, its potential best-in-class Tissue Factor ADC, which has now entered clinical development. The &hellip; Continue reading &quot;Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-12T17:16:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day\",\"datePublished\":\"2025-11-12T17:16:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/\"},\"wordCount\":1237,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/\",\"name\":\"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ=\",\"datePublished\":\"2025-11-12T17:16:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/","og_locale":"en_US","og_type":"article","og_title":"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day - Market Newsdesk","og_description":"&#8211; Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC &#8211;\u00a0 &#8211; Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 &#8211; &#8211; Investor webcast today at 7:00AM PT \/ 10:00AM ET &#8211; SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) &#8212; Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), is hosting a virtual R&amp;D Day today highlighting the details of its platform innovation and next-generation ADC pipeline. The presentation will include an overview of Sutro\u2019s near- and long-term priorities, beginning with STRO-004, its potential best-in-class Tissue Factor ADC, which has now entered clinical development. The &hellip; Continue reading \"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-12T17:16:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day","datePublished":"2025-11-12T17:16:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/"},"wordCount":1237,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/","name":"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ=","datePublished":"2025-11-12T17:16:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3MzQ2MyM3MjU2NjUwIzIxMjM3NjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&amp;D Day"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/909012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=909012"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/909012\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=909012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=909012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=909012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}